CSIMarket
 


Royalty Pharma Plc  (RPRX)
Other Ticker:  
 
 

RPRX's Net Income Growth by Quarter and Year

Royalty Pharma Plc's Net Income results by quarter and year




RPRX Net Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 717.59 -610.03 53.67 477.34
III Quarter September 122.08 220.41 221.80 624.25
II Quarter June 351.34 491.60 806.76 601.98
I Quarter March 509.09 128.08 158.98 -1.62
FY   1,700.10 230.06 1,241.21 1,701.95



RPRX Net Income fourth quarter 2023 Y/Y Growth Comment
Royalty Pharma Plc in the fourth quarter 2023 achieved Net Income of $ 717.59 millions compare to net loss recorded in same quarter a year ago.

Looking into fourth quarter 2023 results within Major Pharmaceutical Preparations industry 6 other companies have achieved higher Net Income growth. While Royalty Pharma Plc' s Net Income no change of % ranks overall at the positon no. 393 in the fourth quarter 2023.




RPRX Net Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - -88.76 % -
III Quarter September -44.61 % -0.63 % -64.47 % -
II Quarter June -28.53 % -39.06 % 34.02 % -
I Quarter March 297.48 % -19.44 % - -
FY   638.98 % -81.46 % -27.07 % -

Financial Statements
Royalty Pharma Plc's fourth quarter 2023 Net Income $ 717.59 millions RPRX's Income Statement
Royalty Pharma Plc's fourth quarter 2022 Net Income $ -610.03 millions Quarterly RPRX's Income Statement
New: More RPRX's historic Net Income Growth >>


RPRX Net Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December 487.8 % - -75.8 % -23.53 %
III Quarter September -65.25 % -55.16 % -72.51 % 3.7 %
II Quarter June -30.99 % 283.82 % 407.46 % -
I Quarter March - 138.64 % -66.69 % -
FY (Year on Year)   638.98 % -81.46 % -27.07 % -




Net Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #7
Healthcare Sector #23
Overall #393

Net Income Y/Y Growth Statistics
High Average Low
638.96 % 47.49 % -81.46 %
(Dec 31 2023)   (Dec 31 2022)
Net Income fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #7
Healthcare Sector #23
Overall #393
Net Income Y/Y Growth Statistics
High Average Low
638.96 % 47.49 % -81.46 %
(Dec 31 2023)   (Dec 31 2022)

Net Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Royalty Pharma Plc's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
487.81 % 77.62 % -75.8 %
(Dec 31 2023)  


RPRX's IV. Quarter Q/Q Net Income Comment
Royalty Pharma Plc achieved in the IV. Quarter 2023 above company average sequential Net Income doubling of 487.8%, to $ 717.59 millions, from $122.08 millions in the third quarter.
Major Pharmaceutical Preparations company is impressively improving, with recording above normal increase, but also improving rate.

Within Major Pharmaceutical Preparations industry Royalty Pharma Plc achieved highest sequential Net Income growth. While Royalty Pharma Plc's Net Income growth quarter on quarter, overall rank is 17.


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #2
Overall #17
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #1
Healthcare Sector #2
Overall #17
Net Income Q/Q Growth Statistics
High Average Low
487.81 % 77.62 % -75.8 %
(Dec 31 2023)  


RPRX's IV. Quarter Q/Q Net Income Comment
Royalty Pharma Plc achieved in the IV. Quarter 2023 above company average sequential Net Income doubling of 487.8%, to $ 717.59 millions, from $122.08 millions in the third quarter.
RPRX is undergoing a remarkable growth, with reporting better then normal increase, and also improving speed, Dahna Ortega, Major Pharmaceutical Preparations industry veteran mentioned.

Within Major Pharmaceutical Preparations industry Royalty Pharma Plc achieved highest sequential Net Income growth. While Royalty Pharma Plc's Net Income growth quarter on quarter, overall rank is 17.


Royalty Pharma Plc's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Net Income 12 Months Ending $ 1,700.09 $ 372.47 $ 470.81 $ 611.07 $ 230.06
Y / Y Net Income Growth (TTM) 638.96 % -58.33 % -47.4 % -49.51 % -81.46 %
Year on Year Net Income Growth Overall Ranking # 403 # 1485 # 1158 # 1016 # 1230
Seqeuential Net Income Change (TTM) 356.43 % -20.89 % -22.95 % 165.61 % -74.26 %
Seq. Net Income Growth (TTM) Overall Ranking # 393 # 720 # 984 # 703 # 1216




Cumulative Net Income growth Comment
With 638.96% annual Net Income growth, Royalty Pharma Plc would report a record annual Net Income surge if the fiscal year would end on Dec 31 2023.

Within the Healthcare sector 23 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 403, from total ranking in previous quarter at 1485.

Net Income TTM Q/Q Growth Statistics
High Average Low
638.96 %
47.49 %
-81.46 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 7
Healthcare Sector # 24
Overall # 403

Net Income TTM Y/Y Growth Statistics
High Average Low
638.96 %
47.49 %
-81.46 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 23
S&P 500 # 393
Cumulative Net Income growth Comment
With 638.96% annual Net Income growth, Royalty Pharma Plc would report a record annual Net Income surge if the fiscal year would end on Dec 31 2023.

Within the Healthcare sector 23 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 403, from total ranking in previous quarter at 1485.

Net Income TTM Q/Q Growth Statistics
High Average Low
638.96 %
47.49 %
-81.46 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 7
Healthcare Sector # 24
Overall # 403

Net Income TTM Y/Y Growth Statistics
High Average Low
638.96 %
47.49 %
-81.46 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 23
S&P 500 # 393




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
RPRX's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for RPRX's Competitors
Net Income Growth for Royalty Pharma Plc's Suppliers
Net Income Growth for RPRX's Customers

You may also want to know
RPRX's Annual Growth Rates RPRX's Profitability Ratios RPRX's Asset Turnover Ratio RPRX's Dividend Growth
RPRX's Roe RPRX's Valuation Ratios RPRX's Financial Strength Ratios RPRX's Dividend Payout Ratio
RPRX's Roa RPRX's Inventory Turnover Ratio RPRX's Growth Rates RPRX's Dividend Comparisons



Companies with similar Net Income surge for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Net Income for the quarter ending Dec 31 2023
Charles River Laboratories International inc -0.08%$ -0.081 millions
Sanuwave Health Inc -0.23%$ -0.232 millions
Regeneron Pharmaceuticals Inc -3.13%$ -3.133 millions
Haemonetics Corporation-5.17%$ -5.169 millions
Resmed Inc -7.16%$ -7.165 millions
Edwards Lifesciences Corporation-7.20%$ -7.204 millions
Star Equity Holdings Inc -9.48%$ -9.481 millions
Bristol myers Squibb Company-12.99%$ -12.988 millions
Gilead Sciences Inc -13.23%$ -13.227 millions
Utah Medical Products Inc-13.50%$ -13.499 millions
Alpha Tau Medical Ltd -13.64%$ -13.640 millions
Masimo Corp-17.13%$ -17.125 millions
Merit Medical Systems Inc-17.28%$ -17.281 millions
Fresenius Medical Care Ag-18.10%$ -18.099 millions
Qiagen N v -19.35%$ -19.354 millions
Mettler toledo International Inc -30.49%$ -30.485 millions
Avantor Inc -30.49%$ -30.487 millions
Sanofi-35.93%$ -35.926 millions
Icu Medical Inc-38.15%$ -38.151 millions
Amedisys Inc -39.71%$ -39.707 millions
Avanos Medical Inc -40.34%$ -40.341 millions
Embecta Corp -42.90%$ -42.898 millions
Pro dex Inc -43.12%$ -43.117 millions
Becton Dickinson And Company-44.79%$ -44.794 millions
Bio techne Corp-45.08%$ -45.075 millions
Harmony Biosciences Holdings inc -45.15%$ -45.150 millions
Exagen Inc -45.72%$ -45.721 millions
Amgen Inc -52.54%$ -52.537 millions
Biogen Inc -54.70%$ -54.704 millions
Taro Pharmaceutical Industries Ltd-56.33%$ -56.330 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com